No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ALXO ALX Oncology
- 6.610
- -1.050-13.71%
Close Jul 18 16:00 ET
- 7.130
- +0.520+7.87%
Post 16:33 ET
344.38MMarket Cap-1781P/E (TTM)
7.770High6.520Low811.48KVolume7.660Open7.660Pre Close5.61MTurnover3.80%Turnover RatioLossP/E (Static)52.10MShares17.82552wk High2.10P/B141.10MFloat Cap3.93652wk Low--Dividend TTM21.35MShs Float117.450Historical High--Div YieldTTM16.32%Amplitude3.936Historical Low6.913Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Piper Sandler Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $21
Piper Sandler analyst Christopher Raymond maintains $ALX Oncology(ALXO.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate of 51.3%
ALX Oncology(ALXO.US) Officer Sells US$10,025.22 in Common Stock
$ALX Oncology(ALXO.US)$ Officer Pinto Shelly sold 1,823 shares of common stock on Jul 5, 2024 at an average price of $5.4993 for a total value of $10,025.22.Source: Announcement What is statement of
ALX Oncology(ALXO.US) Officer Sells US$19,044.93 in Common Stock
$ALX Oncology(ALXO.US)$ Officer Randolph Sophia sold 3,273 shares of common stock on Jul 1, 2024 at an average price of $5.8188 for a total value of $19,044.93.Source: Announcement What is statement o
ALX Oncology(ALXO.US) Officer Sells US$7,989.21 in Common Stock
$ALX Oncology(ALXO.US)$ Officer Pinto Shelly sold 1,373 shares of common stock on Jul 1, 2024 at an average price of $5.8188 for a total value of $7,989.21.Source: Announcement What is statement of ch
ALX Oncology(ALXO.US) Officer Sells US$62,598.65 in Common Stock
$ALX Oncology(ALXO.US)$ Officer Pons Jaume sold 10,758 shares of common stock on Jul 1, 2024 at an average price of $5.8188 for a total value of $62,598.65.Source: Announcement What is statement of ch
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
Comments
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
13
3
$ALX Oncology(ALXO.US$ ALX Oncology Reports Clinical Data From Ongoing Phase 1/2 Investigator-Sponsored Trial Of Evorpacept In Combination With R2 In Patients With Indolent And Aggressive R/R B-NHL
Benzinga· 5 mins ago
The new data were presented in an oral presentation at the 2024 American Association for Cancer Research Annual Meeting. Patients received evorpacept 30 mg/kg Q2W (n=3) or 60 mg/kg Q4W (n=17) in combination with standard R2 treatment. The regimen was well to...
Benzinga· 5 mins ago
The new data were presented in an oral presentation at the 2024 American Association for Cancer Research Annual Meeting. Patients received evorpacept 30 mg/kg Q2W (n=3) or 60 mg/kg Q4W (n=17) in combination with standard R2 treatment. The regimen was well to...
1
$ALX Oncology(ALXO.US$ $ALXO 7,370,690 Shares of Common StockPre-Funded Warrants to Purchase 1,250,000 Shares of Common Stock We are offering 7,370,690 shares of our common stock, par value $0.001 per share (common stock) and, in lieu of common stock to certain investors, pre-funded warrants to
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long